Real estate investment trust NorthWest can amend its pleadings in a lawsuit alleging one of the country’s largest unlisted healthcare property funds conspired to prevent it from acquiring a controlling stake, but has come up short in its bid to add to its claims against property giant Dexus.
Racing NSW has accused its Victorian counterpart of planning an anti-competitive agreement with five other states to exclude it from the thoroughbred racing industry, as it seeks documents to bring potential claims.
A judge has hit the maker of Fairy dishwashing products with an interim injunction that will disrupt the launch of its 30 Minute Miracle detergent, after finding consumer claims by the maker of Finish dishwashing products had a strong prospect of success.
A Federal Court judge has pulled the plug on a bid by the Fair Work Ombudsman for an upcoming trial in wage cases against supermarket giants Coles and Woolworths to be livestreamed like other hearings of public interest in the court.
Liquidators of Sargon Capital are pursuing a claim for $4 million against super trustee firm Diversa and are investigating potential insolvent trading claims against the collapsed fintech’s directors.
The maker of Finish dishwashing detergent has taken Procter & Gamble to court, arguing it misled consumers by claiming its Fairy 30 Minute Miracle dish detergent is more effective than the competition.
Baby food producer Bellamy’s has hit back at a $400,000 lawsuit by its former chief executive officer, saying she was sacked because of “poor financial performance” and not because she complained about sex discrimination.
Insurer Bond & Credit Company has overcome an administrator’s protests and won leave to bring cross-claims against three Greensill entities in lawsuits over the financing firm’s $1.7 billion collapse.
The NSW state racing authority has won access to communications between public relations firm Cato & Clive and five other racing bodies, including Racing Victoria, as it weighs a lawsuit alleging they plotted to exclude the body from the Australian horseracing industry.
German pharmaceutical giant Bayer has slammed generic drug make Sandoz’s late bid for documents, which it called an attempt to “divert and distract” Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.